OH2 Oncolytic Viral Therapy in Pancreatic Cancer

Exclusion Criteria

• •1. Patients diagnosed with pancreatic cancer without pathology and/ or cytology;
• •2. The target lesion has received local non-drug therapy (including radiotherapy, physical and/or chemical ablation, etc.), and no imaging disease progression has occurred；
• •3. Central nervous system metastasis or cancerous meningitis is known to occur. For suspected central nervous system metastasis, head MRI examination is required;
• •4. Patients with Vater's ampullary carcinoma or biliary adenocarcinoma；
• •5. Patients with partial or complete intestinal obstruction and complete biliary obstruction that cannot be relieved by active treatment;
• •6. With more than a moderate amount of ascites, or after conservative medical treatment (such as diuresis, sodium restriction, excluding ascites drainage) for 2 weeks, the ascites still shows a progressive increase；
• •7. A history of other malignant tumors in the past 5 years, except for the following two cases: a. Other malignant tumors treated by a single operation, achieving 5 consecutive years of disease-free survival; b. Cured skin basal cell carcinoma and cured cervical carcinoma in situ;
• •8. Pregnant or lactating female;
• •9. Suffer from severe chronic or active infections, including tuberculosis, syphilis, AIDS (HIV antibody positive)；
• •10. Hypertension that cannot be effectively controlled (defined as systolic/diastolic blood pressure ≥150/100 mmHg or meeting one of them after treatment with standardized antihypertensive drugs); Angina pectoris or unstable angina pectoris occurred within the last 3 months, myocardial infarction or cardiac insufficiency occurred within 1 year before enrollment (heart function ≥ New York Heart Association NYHA grade II); Severe arrhythmia requiring medical treatment, left ventricular ejection fraction \<50%; QTc interval male\>450ms, female\>470ms; Or there are risk factors for torsade de pointes ventricular tachycardia, such as clinically significant hypokalemia as judged by the investigator; Family history of long QT syndrome or family history of arrhythmia (such as WPW syndrome); Schizophrenia, or history of psychotropic drug abuse;
• •11. Suffer from acute or chronic active hepatitis (Hepatitis B reference: HbsAg positive and HBV DNA viral load ≥200IU/mL or ≥10\^3 copies/mL, HCV antibody positive and HCV RNA positive);
• •12. Received any of the following treatments within a certain period of time before enrollment: a.Received second-level or above surgery within 4 weeks (regardless of tumor-related or not), except for minimally invasive surgery under gastrointestinal endoscope; b. Received extended-range radiotherapy within 4 weeks, or received local-range radiotherapy within 2 weeks; c. Other clinical studies have been taken in the past 4 weeks; d. Received local anti-tumor therapy within 4 weeks；
• •13. Toxicity caused by previous anti-tumor therapy before the first dose has not yet recovered to NCI CTCAE version 5.0 grade 0 or 1 (excluding hair loss, skin pigmentation, and non-clinically significant and asymptomatic laboratory abnormalities)；
• •14. Known to be allergic or intolerant to OH2 and its excipients；
• •15. The researchers believe that there is any reason why the patient is not suitable to participate in this trial.